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Epoetin-b is used to treat patients with metastatic cancer undergoing chemotherapy to alleviate the symptoms of anaemia, reduce
the risk of blood transfusions and improve quality of life. This meta-analysis of 12 randomised, controlled studies evaluated the impact
of epoetin-b on overall survival, tumour progression and thromboembolic events (TEEs). A total of 2297 patients were included in
the analysis (epoetin-b, n¼1244; control, n¼1053; 65% solid and 35% nonmyeloid haematological malignancies). A prespecified
subgroup analysis assessed the effects in patients with a baseline Hbp11gdl
 1, corresponding to current European Organisation for
Research and Treatment of Cancer (EORTC) guidelines. No statistically significant effect on mortality was observed with epoetin-b vs
control, both overall (hazard ratio (HR)¼1.13; 95% CI: 0.87, 1.46; P¼0.355) and in patients with baseline Hbp11gdl
 1
(HR¼1.09; 95% CI: 0.80, 1.47; P¼0.579). A trend for a beneficial effect on tumour progression was seen overall (HR¼0.85; 95%
CI: 0.72, 1.01; P¼0.072) and in patients with an Hbp11gdl
 1 (HR¼0.80; 95% CI: 0.65, 0.99; P¼0.041). An increased frequency of
TEEs was seen with epoetin-b vs control (7 vs 4% of patients); however, TEEs-related mortality was similar in both groups (1% each).
The results of this meta-analysis indicate that when used within current EORTC treatment guidelines, epoetin-b has no negative
impact on survival, tumour progression or TEEs-related mortality.
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Anaemia is a common occurrence in patients with cancer, arising
either as a result of the underlying malignant disease, as a
consequence of myelosuppressive chemotherapy or radiotherapy,
or a combination of both (Bokemeyer et al, 2005). Anaemia is
associated with a multitude of symptoms that have a profound
impact on a patient’s condition and quality of life (QoL) (Ludwig
et al, 2004). Furthermore, as an independent prognostic factor,
anaemia has consistently been shown to be associated with adverse
outcomes in patients with a variety of malignancies (Caro et al,
2001).
Erythropoiesis stimulating agents (ESAs) have been shown to
increase Hb levels and reduce transfusion requirements in patients
with cancer (Littlewood et al, 2001; O ¨sterborg et al, 2002;
Vansteenkiste et al, 2002). In addition, treatment with ESAs has
been shown to alleviate fatigue, one of the most distressing
symptoms of anaemia, and result in an improvement in patients’
QoL when compared with placebo or standard transfusion therapy
(Littlewood et al, 2001; Crawford et al, 2002).
Preclinical data have suggested an enhanced tumour response
and delayed tumour progression associated with ESA treatment
(Mittelman et al, 2001; Thews et al, 2001; Stuben et al, 2003).
Moreover, in clinical studies, a potential survival benefit has been
shown in patients undergoing cancer therapy who received
treatment with ESAs (Antonadou et al, 2001; Glaser et al, 2001;
Littlewood et al, 2001). The results of the first meta-analysis of 19
randomised, controlled trials in 2865 cancer patients receiving
ESAs, reported by the Cochrane Group, showed a trend towards
increased survival in patients treated with ESAs (hazard ratio
(HR)¼0.81; 95% CI: 0.67, 0.99; P¼0.04) and lent support to these
findings (Bohlius et al, 2005).
In contrast to the above, two studies, one in patients with head
and neck cancer (Henke et al, 2003) and the other in patients with
breast cancer (Leyland-Jones et al, 2005) found higher rates of
tumour progression and decreased survival, respectively, in
patients receiving ESA treatment compared with placebo. Both
studies had a number of methodologic limitations, including
baseline imbalances and protocol violations, which confounded
the interpretation (Leyland-Jones and Mahmud, 2004; Vaupel and
Mayer, 2004). However, the results of an updated Cochrane meta-
analysis by Bohlius et al (2006) of 57 trials including 9353 patients
also found a shift of the HR for survival (HR¼1.08; 95% CI: 0.99,
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s1.18; P¼0.10) towards an increased risk for patients receiving
various ESAs.
We previously reported the results of a meta-analysis of
nine randomised, controlled studies of epoetin-b conducted in
1403 patients undergoing cancer therapy (Aapro et al, 2006). This
meta-analysis did not demonstrate any evidence that treatment
with epoetin-b impairs survival (HR¼0.97; 95% CI: 0.69, 1.36;
P¼0.87) or promotes tumour progression (HR¼0.78; 95% CI:
0.62, 0.99; P¼0.042). However, one limitation of these findings
was the short duration of follow-up (28 days), particularly for
survival.
The present update to this previous meta-analysis reports the
results from 12 randomised, controlled studies with epoetin-b in
2301 patients receiving anticancer therapy, including three recently
completed trials with longer term follow-up in patients with head
and neck cancer (Henke et al, 2003), patients with metastatic
breast cancer (Aapro et al, 2008) and patients with cervical cancer
(Strauss et al, 2008).
MATERIALS AND METHODS
This updated meta-analysis, using individual patient data, was
designed to evaluate differences between epoetin-b and control
(placebo or standard care) with regard to overall survival, disease
progression and thromboembolic events (TEEs) during and up to
28 days after end of therapy with epoetin-b. Eligible studies
included all randomised, controlled studies of epoetin-b conducted
by the drug sponsor (F Hoffmann-La Roche or Boehringer
Mannheim) in patients with cancer undergoing treatment (chemo-
therapy (seven studies), surgery (two studies), radiotherapy (two
studies) or radio-chemotherapy (one study)). A subgroup analysis
of four controlled studies with extended follow-up provides
information on the effect of epoetin-b on long-term survival and
malignancy progression. Individual study details are summarised
in Table 1.
The primary objectives of the meta-analysis were to evaluate the
effects of epoetin-b on overall survival, disease progression and
TEEs in cancer patients in the overall data set, and for solid
tumours and nonmyeloid haematological malignancies separately.
Secondary predefined objectives included the evaluation of the
potential impact of various Hb intervention levels on mortality and
disease progression as well as evaluation of the latter outcomes in a
predefined subgroup analysis including patients with long-term
follow-up or those with an Hb level at baseline (intervention
Hb)p11gdl
 1.
Most of the studies were originally designed to evaluate the
efficacy of epoetin-b with respect to anaemia correction and thus
there was no follow-up for survival or tumour progression beyond
study treatment plus a standard 28-day period used to assess SAEs,
including deaths and disease progression. Although tumour status
was not prospectively assessed in many of the earlier trials with
short-term follow-up, details of disease progression were routinely
reported as adverse events. For the present meta-analysis, this
information was analysed retrospectively by reviewers blinded to
treatment assignment. Other studies were, however, designed to
assess the effects of epoetin-b on survival and/or disease progres-
sion (Henke et al,2 0 0 3 ;A a p r oet al, 2008) or Hb response to
treatment (Strauss et al, 2008). Long-term follow-up information, up
to 60 months, was available for overall survival in four studies
(Henke et al,2 0 0 3 ;O ¨sterborg et al,2 0 0 5 ;A a p r oet al, 2008;
Strauss et al, 2008) and for tumour progression in three studies
(Henke et al, 2003; Aapro et al, 2008; Strauss et al,2 0 0 8 ) .A l l
reported adverse events were also reviewed against a prespecified
Table 1 Main features of randomised clinical trials of epoetin-b in patients with cancer
Study
Design and
no. of patients
(epoetin-b/control) Diagnosis
Epoetin-b dosage and
duration of therapy Control
Cancer
treatment
ten Bokkel Huinink
et al (1998) (MF4249)
o, pg n¼83/87 Ovarian cancer, Hbo13gdl
 1 150 or 300IUkg
 1
3 week 6 months
Standard
therapy
Chemotherapy
O ¨ sterborg et al (1996)
(MF4250)
o, pg n¼95/49 MM, NHL, CLL; transfusion-dependent,
Hbo10gdl
 1
2000–10000IUday
 1 titrated
or 10000IUday
 1 fixed
dosage 24 weeks
Standard
therapy
Chemotherapy
Rau et al (1998)
(MF4252)
db, pc and pg
n¼28/26
Resectable rectal cancer,
HbX12.5gdl
 1 (men); X12gdl
 1
(women)
200IUkg
 1 daily 11 days Placebo Surgery
Kettelhack et al (1998)
(MF4253)
db, pc n¼52/57 Colorectal cancer suitable for
hemicolectomy, Hb48.5–13.5gdl
 1
20000IUday
 1 10–15 days Placebo Surgery
Data on file (Study
MF4266)
o, pg n¼10/10 AML 10000IUday
 1, then weekly or
twice weekly p30 weeks
Standard
therapy
Chemotherapy
Cazzola et al (1995)
(MF4313)
o, pg n¼117/29 MM, NHL, CLL; transfusion-independent,
Hbp11gdl
 1
1000, 2000, 5000 or
10000IUday
 1 8 weeks
Standard
therapy
Chemotherapy
Oberhoff et al (1998)
(MF4421)
pg, n¼114/104 Solid organ tumours, Hbp11gdl
 1 5000IUday
 1 12–24 weeks Standard
therapy
Chemotherapy
Boogaerts et al (2003)
(MF4321)
o, pg n¼131/128 Malignant disease, Hbp11gdl
 1 150IUkg
 1 3 week adjusted
for Hb response 12 weeks
Standard
therapy
Chemotherapy
O ¨ sterborg et al (2002);
O ¨ sterborg et al (2005)
(MF4467)
pc, db and pg
n¼170/173
MM, NHL, CLL; transfusion-dependent
and epo-deficient, Hbp10gdl
 1
150IUkg
 1 3 week adjusted
for Hb response 16 weeks,
12-month study period*
Placebo Chemotherapy
Henke et al (2003)
(MF4449)
pc, db and pg
n¼171/180
Head and neck cancer, Hbo13gdl
 1
(men), o12gdl
 1 (women)
300IUkg
 1 3 week, 6–8
weeks, 60-month study period
Placebo Radiotherapy
Strauss et al (2008)
(MO16375)
o, pg n¼34/40 Cervical cancer Stage FIGO IIB-IVA,
Hb 9–13gdl
 1
150IUkg
 1 3 week, 8–14
weeks, 6-month study period
Standard
therapy
Radio-chemotherapy
Aapro et al (2008)
(BA16756)
o, pg n¼231/232 Breast cancer, Hb o12.9gdl
 1 30000IU weekly 24 weeks,
24-month study period
Standard
therapy
Chemotherapy
Abbreviations: AML¼acute myeloid leukaemia; CLL¼chronic lymphocytic leukaemia; db¼double-blind; Hb¼haemoglobin; MM¼multiple myeloma; NHL¼non-Hodgkin’s
lymphoma; o¼open design; pc¼placebo-controlled; pg¼parallel group. Patients had anaemia unless stated otherwise, and standard therapy consisted of antitumour treatment
plus blood transfusion as required. *Information on disease progression not collected during the follow-up period of this study.
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slist of TEEs, the definition of which was consistently applied across
all studies.
Statistical analyses
Overall survival and time to progression were analysed by
Kaplan–Meier estimates, log-rank testing and Cox regression
analysis. Thromboembolic events were summarised in terms of
crude rates independent of onset. Time to TEEs was analysed as
for survival and time to progression. Differences in duration of
survival, time to tumour progression and time to TEEs (time
between start of epoetin/control therapy or baseline visit and time
of event) were tested using log-rank tests.
Two sets of analyses were performed. One analysis included data
from all 12 studies. For these analyses, patients without events
were censored at 4 weeks after the last entry in the drug
administration record. A second analysis using only pooled data
from the studies with long-term follow-up, in which all events were
included in the analysis, was performed for overall survival (all
four studies) and time to progression (three studies). In the study
by O ¨sterborg et al (2005), patients were followed for survival but
not for disease progression; therefore; this study was excluded
from the time-to-progression analyses. Patients without an event
were censored at the time of last follow-up or, if no follow-up
information was available, 4 weeks after the last entry in the
administration record.
A predefined subgroup analysis was performed using a
subgroup of patients with a baseline Hb intervention level
corresponding to the European Organisation for Research and
Treatment of Cancer (EORTC) guidelines (i.e., p11gdl
 1).
The primary analysis was based on a simple pooling strategy
without further stratification. Analyses stratified by study were
also performed.
RESULTS
Analysis populations
A total of 2301 patients were enrolled in the 12 trials of whom 2297
(epoetin-b, n¼1244; control, n¼1053) were included in the
analysis; four patients who received no treatment of any kind
during the trials were excluded. All patients who received at least
one dose of study medication were analysed according to the
treatment received. Five patients randomised to control received
epoetin-b and three patients in the epoetin group received no
epoetin-b treatment.
Baseline characteristics and follow-up
Of the 2297 patients in the analysis, 35% had nonmyeloid
haematological malignancies and 65% had solid tumours (Table 2).
Most patients with solid tumours had primary malignancies of the
breast, head and neck, colon/rectum and ovary. Among patients
with nonmyeloid haematological malignancies, the most common
were non-Hodgkin’s lymphoma (56%) and multiple myeloma
(41%). A slightly higher proportion of patients in the epoetin
group had ovarian carcinoma as a result of the three arm design of
the study by ten Bokkel Huinink et al (1998). No other clinically
relevant differences between the groups were noted. Tumour stage
at baseline was not consistently collected in the various studies as
assessment of tumour progression was not a predefined study
objective in most of the earlier studies. However, information on
tumour stage (FIGO or TNM) was available for nearly 70% of
patients with solid tumours. There were no relevant differences
between the treatment arms with respect to tumour staging with
the exception of FIGO Stage III, which was more common in the
epoetin-b arm (16%) than in the control arm (8%) of patients with
solid tumours in which this staging criteria was used.
Mean baseline Hb level was 10.6gdl
 1 in the control arm and
10.5gdl
 1 in the epoetin-b arm. Median initial weekly epoetin-b
dose was 27000IU (range 0–90000IU). During treatment, mean
maximum Hb level was 12.0gdl
 1 in the control arm and
13.4gdl
 1 in the epoetin-b arm. The mean baseline-adjusted Hb
area under the curve was 0.07gdl
 1 with control compared with
1.24gdl
 1 with epoetin-b.
Duration of follow-up across the 12 studies was comparable in
the control (median 3.8 months) and epoetin-b (median 3.9
months) treatment groups (patients without events from the four
studies with long-term follow-up were censored 4 weeks after last
entry in the administration record). In the four studies with long-
term follow-up data, when all events were included, median
follow-up was also comparable (29.8 months with control and 28.8
months with epoetin-b).
Effects on survival
The death rate in the control group was 0.29 deaths per patient-
year and 0.33 in the epoetin-b group (Table 3). There was no
statistically significant difference between patients receiving
epoetin-b or control (standard treatment) in terms of overall
survival in the pooled analysis of all 12 controlled studies (data
collected up to 28 days after last dose) (HR¼of 1.13; 95% CI: 0.87,
1.46; log-rank, P¼0.355) (Figure 1A). Time-to-event analyses,
however, suggested a numerically increased risk for mortality in
the epoetin-b arm vs control with respective overall event rates of
10.9 and 9.4%. Comparable results were found in the pooled
analysis of four studies with long-term follow-up. Mortality rates
Table 2 Baseline characteristics of pooled study populations
Parameter
Control
(N¼1053)
Epoetin-b
(N¼1244)
Gender (% male/female) 37/63 38/62
Race
n 921 1069
Caucasian 882 (96%) 1029 (96%)
Other 39 (4%) 40 (4%)
Mean age in years (range) 58.8 (19–91) 59.3 (20–87)
Mean weight in kg (range) 67.7 (30.0–131.5) 67.1 (35.0–118.0)
n 1048 1235
Mean height in cm (range) 166.7 (140–198) 166.4 (126–198)
n 809 1012
Tumour type, n (%)
Haematological 331 (31.4) 465 (37.4)
Acute myeloid leukaemia 10 (3.0) 10 (2.2)
Multiple myeloma 125 (37.8) 204 (43.9)
Non-Hodgkin’s lymphoma 195 (58.9) 247 (53.1)
Hodgkin’s lymphoma 1 (o1) 4 (o1)
Solid 722 (68.6) 779 (62.6)
Breast 261 (36.2)
Head/neck 174 (24.1) 261 (33.5)
Gynaecological 133 (18.4) 181 (23.2)
Gastrointestinal 96 (13.3) 186 (23.9)
Other 58 (8.0) 100 (12.8)
51 (6.6)
Haemoglobin
N 1050 1241
Mean (range) 10.6 (5.7–16.7) 10.5 (4.2–17.1)
Median 10.5 10.4
Data were collected from all 2297 patients unless otherwise stated.
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epoetin-b groups, respectively. Median survival was 20.6 months
for control and 17.8 months for epoetin-b, with overall event rates
of 60.5 and 64.5% and an HR of 1.13 (95% CI: 0.98, 1.31; log-rank,
P¼0.082) (Table 3). It is worth noting that the trend observed in
this substudy analysis was due to the larger number of events
associated with a longer follow-up.
In both the analysis of the pooled population of 12 controlled
studies (including events up to 28 days after end of treatment) and
the analysis of four studies with long-term follow-up, the risk of
death for patients with solid tumours (HR¼1.17; 95% CI: 0.83,
1.64 and HR¼1.17; 95% CI: 0.99, 1.39, respectively) was similar to
that in the overall pooled population (HR¼1.13; 95% CI: 0.87, 1.46
and HR¼1.13; 95 % CI: 0.98, 1.31, respectively), however, it was
lower for patients with nonmyeloid haematological malignancies
(HR¼1.04; 95% CI: 0.69, 1.55 and HR¼1.04; 95% CI: 0.80, 1.36,
respectively) (Table 3).
In the subgroup of patients with baseline Hbp11gdl
 1 from the
pooled analysis of 12 controlled studies (N¼1426) (i.e., in line
with current EORTC guidelines), the overall event rate was
comparable (11.5 and 12.5% for control and epoetin-b, respec-
tively), and time-to-event analyses showed a HR of 1.09 (95%
CI: 0.80, 1.47; log-rank, P¼0.580) (Figure 2A). In the pooled
population of four studies with long-term follow-up, the overall
event rate was 68% for control and 70% for epoetin-b; median
survival was 15.9 months in both treatment arms and the estimated
HR¼1.03 (95% CI: 0.85, 1.25; log-rank, P¼0.750).
No significant differences in overall survival were seen between
epoetin-b and control in patients with solid tumours or
nonmyeloid haematological malignancies in the subgroup of
patients with baseline Hbp11gdl
 1 (Figure 3A).
Effects on disease progression
No significant differences between the epoetin-b and control
groups were seen in the number of patients with disease
progression in the overall study population. The rates of disease
progression were lower in patients receiving epoetin-b (0.74 events
per patient-year) as compared to those in the control arm (0.86
events per patient-year)(Table 3). In the overall pooled population
of the 12 controlled randomised studies, Kaplan–Meier analysis
indicated a similar risk of progression, with a trend in favour of a
reduced risk among patients treated with epoetin-b (HR¼0.85;
95% CI: 0.72, 1.01; log-rank, P¼0.072) (Figure 1B). In both
subgroups of patients with solid or nonmyeloid haematological
tumours, the HRs for disease progression were similar to that for
the overall population (Table 3).
In the pooled analysis of the three studies where long-term
disease progression follow-up was recorded, the rate of disease
progression was higher (0.62 events per patient-year) compared
with those in the control arm (0.54 events per patient-year). The
overall event rate was 59% with control and 61% with epoetin-b,
and the risk of progression was similar, with a trend for a higher
risk of disease progression in patients receiving epoetin-b
(HR¼1.13; 95% CI: 0.95, 1.34; log-rank, P¼0.165) (Table 3).
Median time to progression was 11.2 months with control and 9.8
months with epoetin-b.
In the subgroup of patients with baseline Hbp11gdl
 1, in the
pooled analysis of 12 controlled studies, the percentage of patients
with disease progression was lower with epoetin-b (22.2%) than
with control (27.0%). Similarly, in the pooled analysis of studies
with long-term follow-up, a lower percentage of patients in the
epoetin-b arm had disease progression (61.0%) compared with the
control arm (69.4%). Time-to-event analyses showed a reduced
risk of progression for patients with a baseline Hbp11gdl
 1
receiving epoetin-b in the pooled analysis of 12 controlled studies
(HR¼0.80; 95% CI: 0.65, 0.99; log-rank, P¼0.041) (Figure 2B) and
a trend towards a reduced risk with epoetin-b in the pooled
analysis of three studies with long-term follow-up (HR¼0.85; 95%
CI: 0.64, 1.13; log-rank, P¼0.267).
No significant differences in time to progression were seen
between epoetin-b and control in patients with solid tumours or
Table 3 Kaplan–Meier and Cox regression analysis of survival and time-to-event data
Control (N¼1053) Epoetin-b (N¼1244)
Patient group
Total
events
Mean patient-years
of follow-up
Events per
patient-year
Total
events
Mean patient-years
of follow-up
Events per
patient-year
Hazard
ratio (95% CI) P-value
a
Pooled population of 12 controlled studies
Overall survival
Total 99 0.32 0.29 136 0.33 0.33 1.13 (0.87–1.46) 0.355
Solid 58 0.32 0.25 78 0.34 0.30 1.17 (0.83–1.64)
Non-myeloid haematological 41 0.34 0.37 58 0.32 0.39 1.04 (0.69–1.55)
Time to progression
Total 254 0.28 0.86 268 0.29 0.74 0.85 (0.72–1.01) 0.072
Solid 171 0.27 0.88 173 0.29 0.76 0.85 (0.68–1.05)
Non-myeloid haematological 82 0.31 0.81 93 0.29 0.69 0.84 (0.62–1.13)
Time to thromboembolic event
Total 46 0.32 0.14 88 0.32 0.22 1.62 (1.13–2.31) 0.008
Solid 29 0.32 0.13 61 0.33 0.24 1.92 (1.24–2.99)
Non-myeloid haematological 17 0.34 0.15 27 0.32 0.18 1.18 (0.64–2.16)
Pooled population of studies with long-term follow-up
Overall survival
Total 371 1.54 0.39 396 1.45 0.44 1.13 (0.98–1.31) 0.082
Solid 262 1.61 0.37 286 1.49 0.43 1.17 (0.99–1.39)
Non-myeloid haematological 109 1.37 0.46 110 1.36 0.48 1.04 (0.80–1.36)
Time to progression
Total
b 260 1.10 0.54 270 0.98 0.62 1.13 (0.95–1.34) 0.165
aLog-rank test P-value epoetin-b vs placebo/control.
bAll studies were in patients with solid tumours; ‘events’ refers to number of deaths for ‘overall survival’, number of malignant
disease progressions for ‘time to progression’ and number of thromboembolic events for ‘time to thromboembolic event’.
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snonmyeloid haematological malignancies in the subgroup of
patients with baseline Hbp11gdl
 1 (Figure 3B).
Effects on thromboembolic events
Across the 12 studies in the pooled analysis, there is a statistically
significantly shorter time to TEEs in the epoetin-b group
compared with control (P¼0.0075, log-rank test). Furthermore,
a higher incidence of TEEs was seen with epoetin-b (7.1%) vs
control (4.4%), largely due to reports of deep vein thrombosis (1.3
vs 0.4%), thrombophlebitis (0.6 vs 0.3%) and pulmonary embolism
(1.2 vs 0.9%). However, there was no difference in the incidence of
fatal TEEs between the treatment arms (1% each), the most
common being pulmonary embolism.
The TEEs rate was higher in the epoetin-b group (0.22 events per
patient-year) compared with the control (0.14 events per patient-
year) with an overall HR for time to TEEs of 1.62 (95% CI: 1.13,
2.31; log-rank, P¼0.008). The risk of TEEs in patients receiving
epoetin-b was higher in the subgroup of patients with solid
tumours (HR¼1.92; 95% CI: 1.24, 2.99) than in those with
nonmyeloid haematological malignancies (HR¼1.18; 95% CI:
0.64, 2.16) (Table 3).
Sensitivity analyses
Results from analyses adjusting by study yielded results consistent
with the primary analysis (data not shown).
DISCUSSION
The results of the meta-analysis of 12 randomised controlled
studies in patients with solid tumours or nonmyeloid haema-
tological tumours (n¼2297) treated with epoetin-b or control/
placebo do not show any significant negative effect of epoetin-b on
survival or tumour progression. Importantly, this updated
meta-analysis also includes long-term follow-up data from more
recent studies and largely confirms the results of the earlier meta-
analysis of nine controlled studies (n¼1413) (Aapro et al, 2006),
which did not include the recently completed studies by Henke
et al (2003); Aapro et al (2008) and Strauss et al (2008). Moreover,
this update confirms the safety of epoetin-b in terms of overall
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Figure 1 Kaplan–Meier curves of (A) overall survival and (B) time to progression in the pooled population of 12 controlled studies.
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ssurvival and disease progression when used within current EORTC
guidelines with respect to an intervention Hb levelp11gdl
 1.
Overall survival
The results for overall survival are consistent with the findings
from a recently updated meta-analysis of published, randomised
clinical trials in patients with cancer receiving chemotherapy by
the Cochrane Collaboration (Bohlius et al, 2006). A shift of the
overall HR for mortality towards a more favourable outcome for
patients in the control group compared to those receiving ESA
treatment is different from the results of an earlier meta-analysis
by the same group where a trend towards increased survival in
patients treated with ESAs was shown (Bohlius et al, 2005).
However, as in the present updated meta-analysis of controlled
clinical trials with epoetin-b, the results of the updated meta-
analysis seem to be driven by inclusion of data from studies, which
allowed enrollment of patients with a baseline Hb up to and above
13gdl
 1. The outcomes reported in these trials have been either
negative (Henke et al, 2003, Leyland-Jones et al, 2005) or neutral
(Aapro et al, 2008; Strauss et al, 2008). An Hb initiation level above
11gdl
 1 is not in line with the current EORTC treatment
recommendations (Bokemeyer et al, 2007). The subgroup analyses
in our updated meta-analysis for epoetin-b are fully supportive of
this conclusion.
To date, the results of two prospective, randomised studies
suggesting that ESA treatment may have a negative impact
on survival have been published in detail (Henke et al, 2003;
Leyland-Jones et al, 2005). A negative impact of ESA treatment on
survival is also suggested by three recent studies (Overgaard et al,
2007; Wright et al, 2007; Smith et al, 2008), two of which
(Overgaard et al, 2007; Smith et al, 2008) have not yet been
reported in full. The findings of Henke et al (2003) and Leyland-
Jones et al (2005) should, however, be interpreted with caution as a
number of limitations associated with the studies have been
identified including baseline imbalances in prognostic factors,
which favoured the placebo arm in both (Dunst 2004; Leyland-
Jones and Mahmud, 2004; Vaupel and Mayer, 2004). Similar
caution has to be exercised with respect to the interpretation of the
other three studies mentioned above as they were either not
designed to assess survival, have been terminated early, with a very
limited sample size (Wright et al, 2007), have not been fully
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Figure 2 Kaplan–Meier curves of (A) overall survival and (B) time to progression in patients with a baseline Hbp11gdl
 1 in the pooled population of
12 controlled studies.
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receiving chemotherapy (Smith et al, 2008 ) and do therefore not
allow a conclusive interpretation. A common feature of these five
studies is that all were conducted outside the currently approved
indications and all were performed in predominantly mild or
nonanaemic patients, with target Hb levels higher than those
recommended by the EORTC guidelines (Bokemeyer et al, 2007),
for the use of ESA therapy in cancer patients treated with
chemotherapy.
Tumour progression
The results in this updated meta-analysis do not suggest an
increased risk for disease progression in patients receiving
epoetin-b treatment vs those receiving standard care, but show
the risk to be similar, with a trend towards a reduction in risk
favouring patients receiving epoetin-b. When this analysis was
restricted to patients with Hb intervention levels of p11gdl
 1 in
line with recent EORTC guidelines (Bokemeyer et al, 2007), the
results showed a statistically significantly lower risk for disease
progression in patients receiving epoetin-b. A similar finding of a
more favourable outcome with respect to tumour progression in
patients treated with ESA vs control was recently reported by the
Cochrane Collaboration (Bohlius et al, 2006), as well as in a
systematic review of 46 ESA trials conducted for the National
Institute of Clinical Excellence (NICE) (Wilson et al,2 0 0 7 ) .W h e t h e r
the obvious discrepancy between outcomes of disease progression
favouring epoetin treatment and survival outcomes favouring
control/placebo treatment may be caused by an underdiagnosis of
fatal TEEs (see section below) must remain speculative.
Category Subgroup
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0.57 0.77 1.04
Figure 3 Summary of hazard ratios for (A) overall survival and (B) time to progression in subgroup of patients with baseline Hbp11gdl
 1.
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The present analysis showed a significantly increased TEEs
rate with epoetin-b compared with control (7 vs 4%; P¼0.008).
These results are consistent with those reported in both meta-
analyses of the Cochrane Collaboration (Bohlius et al, 2005, 2006).
The risk of TEEs was shown to be higher in the subgroup of
patients with solid tumours compared with those with nonmyeloid
haematological malignancies. This may be driven mainly by the
differences in TEEs risk in the underlying cancer population due to
disease stage and activation of the coagulation system. Despite the
well-known increased incidence of TEEs associated with epoetin-b
treatment in the present analysis, importantly, the incidence of TEEs-
related mortality was similar between the two treatment groups (1% in
each group).
CONCLUSIONS
The results of this meta-analysis including all prospective,
randomised studies conducted with epoetin-b in cancer patients
showed no evidence for a significantly negative effect of epoetin-b
treatment on survival in patients with metastatic cancer. Further-
more, there was no negative effect of epoetin-b on tumour
progression. The risk of TEEs was consistent with the increased
TEEs risk observed within the ESA class in general, with a higher
incidence of TEEs in patients with solid tumours. Predefined
subgroup analyses in patients with an initiation Hb level
corresponding to the current EORTC treatment guidelines (i.e.,
Hbp11gdl
 1) confirm the safety of epoetin-b in the treatment of
anaemia in patients with metastatic cancers receiving concurrent
chemotherapy when used within its licensed indication.
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